Millennium Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.5M Sell
471,284
-992,664
-68% -$70M 0.01% 1216
2025
Q4
$98.5M Buy
1,463,948
+236,364
+19% +$15.9M 0.04% 440
2025
Q3
$90M Buy
1,227,584
+537,111
+78% +$35.7M 0.04% 495
2025
Q2
$35.9M Buy
690,473
+648,239
+1,535% +$36.9M 0.02% 1045
2025
Q1
$2.69M Sell
42,234
-53,190
-56% -$3.09M ﹤0.01% 3495
2024
Q4
$4.56M Buy
95,424
+68,505
+254% +$3.51M ﹤0.01% 2894
2024
Q3
$1.54M Sell
26,919
-396,271
-94% -$22.7M ﹤0.01% 3938
2024
Q2
$22.2M Buy
423,190
+291,122
+220% +$12.8M 0.01% 1401
2024
Q1
$5.37M Sell
132,068
-178,838
-58% -$6.7M ﹤0.01% 2796
2023
Q4
$11.5M Sell
310,906
-590,539
-66% -$22.2M 0.01% 2053
2023
Q3
$34.4M Sell
901,445
-908,364
-50% -$37.2M 0.02% 975
2023
Q2
$65.3M Buy
1,809,809
+791,020
+78% +$27M 0.03% 574
2023
Q1
$38.9M Buy
1,018,789
+967,665
+1,893% +$45.4M 0.02% 853
2022
Q4
$2.91M Sell
51,124
-921,614
-95% -$47.2M ﹤0.01% 3241
2022
Q3
$38.5M Buy
972,738
+905,754
+1,352% +$40M 0.02% 842
2022
Q2
$2.95M Buy
66,984
+3,746
+6% +$162K ﹤0.01% 3328
2022
Q1
$2.52M Sell
63,238
-96,860
-61% -$3.45M ﹤0.01% 3647
2021
Q4
$6.44M Sell
160,098
-105,175
-40% -$3.93M ﹤0.01% 2642
2021
Q3
$10.8M Buy
265,273
+49,650
+23% +$2.08M 0.01% 1957
2021
Q2
$9.79M Buy
215,623
+183,797
+578% +$8.14M 0.01% 1938
2021
Q1
$1.33M Sell
31,826
-285,349
-90% -$13M ﹤0.01% 3920
2020
Q4
$13.5M Buy
+317,175
New +$11.4M 0.01% 1403
2020
Q3
Sell
-42,658
Closed -$1.14M 4598
2020
Q2
$1.14M Sell
42,658
-402,044
-90% -$9.07M ﹤0.01% 2917
2020
Q1
$8M Sell
444,702
-610,261
-58% -$11.6M 0.02% 1007
2019
Q4
$18.7M Buy
1,054,963
+739,802
+235% +$12.8M 0.02% 895
2019
Q3
$4.89M Buy
+315,161
New +$5.19M 0.01% 1823
2018
Q4
Sell
-73,996
Closed -$1.34M 3913
2018
Q3
$1.34M Sell
73,996
-8,718
-11% -$153K ﹤0.01% 2698
2018
Q2
$1.4M Sell
82,714
-1,290,533
-94% -$24.4M ﹤0.01% 2643
2018
Q1
$26.9M Sell
1,373,247
-101,896
-7% -$1.97M 0.04% 722
2017
Q4
$29.9M Buy
1,475,143
+733,706
+99% +$13.5M 0.04% 658
2017
Q3
$12.9M Buy
741,437
+151,178
+26% +$2.05M 0.02% 1081
2017
Q2
$7.57M Buy
590,259
+350,572
+146% +$4.68M 0.01% 1228
2017
Q1
$3.11M Sell
239,687
-144,412
-38% -$1.83M 0.01% 1742
2016
Q4
$3.79M Buy
384,099
+164,001
+75% +$1.8M 0.01% 1512
2016
Q3
$2.66M Sell
220,098
-150,187
-41% -$1.53M ﹤0.01% 1752
2016
Q2
$3.2M Buy
370,285
+77,857
+27% +$768K 0.01% 1526
2016
Q1
$2.77M Buy
292,428
+216,988
+288% +$2.04M 0.01% 1609
2015
Q4
$1.31M Sell
75,440
-2,991,946
-98% -$47.7M ﹤0.01% 2162
2015
Q3
$41.2M Sell
3,067,386
-2,433,305
-44% -$48.9M 0.08% 295
2015
Q2
$124M Buy
5,500,691
+750,563
+16% +$13.2M 0.23% 75
2015
Q1
$67.8M Buy
4,750,128
+4,032,870
+562% +$58.2M 0.13% 170
2014
Q4
$6.92M Buy
717,258
+412,969
+136% +$3.67M 0.01% 1192
2014
Q3
$2.77M Buy
304,289
+40,864
+16% +$389K 0.01% 1658
2014
Q2
$2.6M Buy
+263,425
New +$2.23M 0.01% 1601
2014
Q1
Sell
-152,360
Closed -$2.28M 3634
2013
Q4
$2.28M Buy
152,360
+128,254
+532% +$1.65M 0.01% 1733
2013
Q3
$266K Sell
24,106
-118,788
-83% -$990K ﹤0.01% 2937
2013
Q2
$1.14M Buy
+142,894
New +$910K ﹤0.01% 1894

Other funds holding HALO

Millennium Management's HALO Position: Q1 2026 in Review

Millennium Management reduced its Halozyme (HALO) stake by 68% in Q1 2026, selling an estimated $70M and leaving 471,284 shares worth $30.5M. The position accounts for 0.01% of the portfolio, ranked #1216.

Millennium Management first reported a position in HALO in Q2 2013 and has held it in 47 quarters since. The position peaked at $124M in Q2 2015. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Millennium Management held 471,284 shares of Halozyme worth $30.5M as of Q1 2026.
  • Millennium Management sold 992,664 Halozyme shares in Q1 2026, an estimated $70M.
  • Halozyme made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1216 holding.
  • Millennium Management first reported a position in Halozyme in Q2 2013 and has held it in 47 quarters since.
  • Millennium Management's Halozyme position peaked at $124M in Q2 2015.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.